Dnage B.V. | Date: 2007-06-26
Pharmaceutical preparations for the treatment of age-related diseases and disorders, biological and chemical preparations for medical use, dietetic foods and beverages adapted for medical use; dietetic sugar for medical use; medicated creams for skin care, namely, pharmaco-cosmetic creams for skin care available only on prescription; medicated lotions for the body, namely, pharmaco-cosmetic lotions for the body available only on prescription.
Agency: Cordis | Branch: FP7 | Program: CP-IP | Phase: HEALTH-2007-2.2.2-3 | Award Amount: 15.91M | Year: 2008
The rate of ageing in humans is not uniform, due to genetic heterogeneity and the influence of environmental factors. Age-related changes in body function or composition that could serve as a measure of biological age and predict the onset of age-related diseases and/or residual lifetime are termed biomarkers of ageing. Many candidate biomarkers have been proposed but in all cases their variability in cross-sectional studies is considerable, and therefore no single measurement has so far proven to yield a useful biomarker of ageing on its own, probably due to the multi-causal and multi-system nature of ageing. We propose to conduct a population study (3,300 probands) to identify a set biomarkers of ageing which, as a combination of parameters with appropriate weighting, would measure biological age better than any marker in isolation. Two large groups of subjects will be recruited, i.e. (1) randomly recruited age-stratified individuals from the general population covering the age range 35-74 years and (2) subjects born from a long-living parent belonging to a family with long living sibling(s) already recruited in the framework of the GEHA project. For genetic reasons such individuals (GEHA offspring) are expected to age at a slower rate. They will be recruited together with their spouses as controls, thus allowing initial validation of the biomarkers identified. (3) A small number of patients with progeroid syndromes will also be included in the study. A wide range of candidate biomarkers will be tested, including (a) classical ones for which data from several smaller studies have been published; (b) new ones, based on recent preliminary data, as well as (c) novel ones, based on recent research on mechanistic aspects of ageing, conducted by project participants. Bioinformatics will be used in order to extract a robust set of biomarkers of human ageing from the large amounts of data to be generated and to derive a model for healthy ageing.
Dnage B.V. | Date: 2007-11-13
Pharmaceutical preparations for the treatment of premature aging diseases, namely, cockayne syndrome.